Sugi Predict

Sugi Predict / Targets / ADCY5

ADCY5

Adenylate cyclase type 5 · O95622 · ADCY5 on Sugi Atlas →

9,620 patent compounds predicted against ADCY5, 5,537 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL111590 SCHEMBL111590 0.74 14/20
SCHEMBL979020 SCHEMBL979020 1.00 13/20
Succinic Acid Succinic Acid (SCHEMBL1197778) 0.55 11/20
SCHEMBL987094 SCHEMBL987094 0.64 9/20
SCHEMBL979021 SCHEMBL979021 0.55 9/20
SCHEMBL1919194 SCHEMBL1919194 0.53 7/20
SCHEMBL2653753 SCHEMBL2653753 0.51 7/20
SCHEMBL2654576 SCHEMBL2654576 0.51 7/20
SCHEMBL2019803 SCHEMBL2019803 0.37 7/20
SCHEMBL2653428 SCHEMBL2653428 0.58 6/20
SCHEMBL2653879 SCHEMBL2653879 0.57 6/20
SCHEMBL600632 SCHEMBL600632 0.51 6/20
SCHEMBL600633 SCHEMBL600633 0.51 6/20
SCHEMBL599248 SCHEMBL599248 0.50 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1575756) 0.47 6/20
Abacavir Abacavir (SCHEMBL51932) 0.47 6/20
Abacavir Abacavir (SCHEMBL51933) 0.47 6/20
Abacavir Abacavir (SCHEMBL1575076) 0.47 6/20
Abacavir Abacavir (SCHEMBL2329017) 0.46 6/20
Phosphoramidic Acid Phosphoramidic Acid (SCHEMBL110377) 0.46 6/20

Clinical trials — most relevant to ADCY5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals PHASE1/PHASE2COMPLETED
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease PHASE2ACTIVE_NOT_RECRUITING
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients PHASE1/PHASE2COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram PHASE1COMPLETED
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses PHASE1UNKNOWN
Caffeine Efficacy in ADCY5-related Dyskinesia nanUNKNOWN
Assessment of ADCY5-related Movement Disorders With Motion SENSors nanCOMPLETED
Pilot Study on Caffeine Efficiency in ADCY5-related Dyskinesia nanCOMPLETED
Stress and Treatment Response in Puerto Rican Children With Asthma nanCOMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow nanCOMPLETED
Insulin Detemir in Obesity Management nanACTIVE_NOT_RECRUITING
The Effects of Tailored Judo Training and Nutritional Counseling on Physical Fitness and Body Composition in Children With Autism: A Study Including Blood Morphology and Genetic Analysis nanCOMPLETED
The Effects of Capsinoids on Brown Adipose Tissue Activation in Obesity nanCOMPLETED
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ADCY5 binder may also engage these)

ProteinNameSimilarity
P40144 — 1.000 P40144 →
P84309 — 1.000 P84309 →
Q04400 — 0.999 Q04400 →
P30803 — 0.998 P30803 →
ADCY6 Adenylate cyclase type 6 (EC 4.6.1.1) (ATP py 0.997 landscape →
P30804 — 0.997 P30804 →
Q9DGG6 — 0.995 Q9DGG6 →
Q01341 — 0.993 Q01341 →
P98999 — 0.992 P98999 →
ADCY9 Adenylate cyclase type 9 0.991 landscape →
Q9VW60 — 0.991 Q9VW60 →
Q9TUI4 — 0.991 Q9TUI4 →
Q03343 — 0.991 Q03343 →
P51830 — 0.991 P51830 →
ADCY3 Adenylate cyclase type 3 0.990 landscape →
P40146 — 0.990 P40146 →
P32870 — 0.989 P32870 →
ADCY8 Adenylate cyclase type 8 0.988 landscape →
O54853 — 0.987 O54853 →
A2WYE9 — 0.987 A2WYE9 →
P97490 — 0.986 P97490 →
P54282 — 0.986 P54282 →
Q0JGK4 — 0.986 Q0JGK4 →
Q5B0V6 — 0.986 Q5B0V6 →
Q9UPV7 — 0.986 Q9UPV7 →
Q8VHH7 — 0.986 Q8VHH7 →
P51829 — 0.986 P51829 →
O08703 — 0.986 O08703 →
P97445 — 0.985 P97445 →
KCNH2 Voltage-gated inwardly rectifying potassium channel KCNH2 0.985 landscape →